INS and metabolic syndrome: Hence, by reducing circulating insulin and glucose levels it is postulated that metformin may reduce insulin-mediated tumorigenesis and cancer progression, perhaps most relevant to patients with metabolic syndrome or type 2 diabetes although metformin has been shown to reduce insulin levels in cancer patients without these conditions [17].